The study of the effect of the low molecular analog of neuropeptide Y on behavioral reactions in rats




neuropeptide Y, stress, open field, elevated plus-maze, behavioral disorders


It is known that along with the main stress-adaptive systems, one of the decisive places is occupied by the biologically active peptide – neuropeptide Y (NPY). NPY is a biologically active compound of peptide nature, which is capable to activate 4 different subtypes of NPY receptors in mammals. The prevalence of NPY receptors determines that the system of NPY and NPY receptors is involved in the regulation of many physiological functions, including the feeling of satiety and hunger, circadian rhythms, response to stress, learning, regulation of the vascular tone, sleep, sexual behavior, etc.
Аim. To study the effect of the low molecular analog of neuropeptide Y on the behavioral response of rats in the tests “open field” and “elevated plus-maze”.
Materials and methods. The study object was a modified terminal NPY fragment containing 9 amino acid residues. The experimental animals received intranasally a solution of the peptide studied in the dose of 0.02 mg/kg, 0.05 mg/kg and 0.1 mg/kg. The pharmacological study of the effect of the compound on the behavioral reactions of rats was performed using the tests “open field” and “elevated plus-maze”.
Results. Experiments in rats showed the presence of anxiolytic properties of the compound without the associated sedative effect. In the tests “open field” and “elevated plus-maze”, the activating effect of the compound on the locomotor activity and a decrease in vegetative manifestations were observed.
Conclusions. The data obtained indicate that the neuropeptide Y modified fragment is able to affect the anxiety level and research activity of rats; it substantiates the feasibility of further studies of this experimental compound.

Author Biographies

A. L. Zagayko, National University of Pharmacy

Doctor of Biology, professor of the Biochemistry Department, vice-rector for Science and Education

I. O. Havrylov, National University of Pharmacy

PhD student of the Biochemistry Department

D. V. Lytkin, National University of Pharmacy

deputy director of SEIAP


Reichmann, F., & Holzer, P. (2016). Neuropeptide Y: A stressful review. Neuropeptides, 55, 99–109.

Yi, M., Li, H., Wu, Z., Yan, J., Liu, Q., Ou, C., & Chen, M. (2017). A Promising Therapeutic Target for Metabolic Diseases: Neuropeptide Y Receptors in Humans. Cellular Physiology and Biochemistry, 45(1), 88–107.

Benarroch, E. E. (2009). Neuropeptide Y: Its multiple effects in the CNS and potential clinical significance. Neurology, 72(11), 1016–1020.

Eaton, K., Sallee, F., & Sah, R. (2007). Relevance of Neuropeptide Y (NPY) in Psychiatry. Current Topics in Medicinal Chemistry, 7(17), 1645–1659.

Thorsell, A., & Ehlers, C. L. (2006). Neuropeptide Y in Brain Function. Handbook of Neurochemistry and Molecular Neurobiology, 523–543.

Sabban, E. L., Alaluf, L. G., & Serova, L. I. (2016). Potential of neuropeptide Y for preventing or treating post-traumatic stress disorder. Neuropeptides, 56, 19–24.

Kash, T. L., & Winder, D. G. (2006). Neuropeptide Y and corticotropin-releasing factor bi-directionally modulate inhibitory synaptic transmission in the bed nucleus of the stria terminalis. Neuropharmacology, 51(5), 1013–1022.

Narváez, M., Borroto-Escuela, D. O., Santín, L., Millón, C., Gago, B., Flores-Burgess, A., … Fuxe, K. (2018). A Novel Integrative Mechanism in Anxiolytic Behavior Induced by Galanin 2/Neuropeptide Y Y1 Receptor Interactions on Medial Paracapsular Intercalated Amygdala in Rats. Frontiers in Cellular Neuroscience, 12.

Meredith, M. E., Salameh, T. S., & Banks, W. A. (2015). Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases. The AAPS Journal, 17(4), 780–787.

Beck-Sickinger, A. G., Weland, H. A., Wittneben, H., Willim, K.-D., Rudolf, K., & Jung, G. (1994). Complete L-Alanine Scan of Neuropeptide Y Reveals Ligands Binding to Y1 and Y2 Receptors with Distinguished Conformations. European Journal of Biochemistry, 225(3), 947–958.

Zambello, E., Zanetti, L., Hédou, G. F., Angelici, O., Arban, R., Tasan, R. O., … Caberlotto, L. (2011). Neuropeptide Y-Y2 receptor knockout mice: influence of genetic background on anxiety-related behaviors. Neuroscience, 176, 420–430.

Lach, G., & de Lima, T. C. M. (2013). Role of NPY Y1 receptor on acquisition, consolidation and extinction on contextual fear conditioning: Dissociation between anxiety, locomotion and non-emotional memory behavior. Neurobiology of Learning and Memory, 103, 26–33.

Tan, C. M. J., Green, P., Tapoulal, N., Lewandowski, A. J., Leeson, P., & Herring, N. (2018). The Role of Neuropeptide Y in Cardiovascular Health and Disease. Frontiers in Physiology, 9.

Herring, N., Lokale, M. N., Danson, E. J., Heaton, D. A., & Paterson, D. J. (2008). Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway. Journal of Molecular and Cellular Cardiology, 44(3), 477–485.

Tran, L. V., Somogyi, G. T., & De Groat, W. C. (1994). Inhibitory effect of neuropeptide Y on adrenergic and cholinergic transmission in rat urinary bladder and urethra. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 266(4), R1411–R1417.

Quarta, D., Leslie, C. P., Carletti, R., Valerio, E., & Caberlotto, L. (2011). Central administration of NPY or an NPY-Y5 selective agonist increase in vivo extracellular monoamine levels in mesocorticolimbic projecting areas. Neuropharmacology, 60(2-3), 328–335.

Schlicker, E., Gro ß, G., Fink, K., Glaser, T., & Göthert, M. (1991). Serotonin release in the rat brain cortex is inhibited by neuropeptide Y but not affected by ACTH1?24 angiotensin II, bradykinin and delta-sleep-inducing peptide. Naunyn-Schmiedeberg’s Archives of Pharmacology, 343(2), 117–122.





Pre-clinical studies of new drugs